GENE LOGIC AND ROCHE ENTER COLLABORATION TO DISCOVER NEW DEVELOPMENT PATHS

A A

Gene Logic Inc. (NASDAQ:GLGC) announced today that it has entered into a drug repositioning and development agreement with Roche to seek alternative development paths for multiple Roche drug candidates. All of these drug candidates have successfully passed Phase I human clinical trials, and were discontinued in Phase II or Phase III clinical trials. Similar to development-stage in-licensing deals, the agreement provides for Gene Logic to receive success-based milestone payments for each drug candidate Roche returns to clinical development. In addition, Gene Logic will receive royalties for each marketed drug.

Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20051208005164&newsLang=en)